Lilly's Billion-Dollar Deal With CureVac For 'Next Generation' Immunotherapies

Lilly is targeting mRNA-based next-generation immunotherapies in its collaboration with Germany's CureVac, which could be worth more than $1.7bn for the family-office backed biotech.

Keys
Do immunotherapies hold the key to cancer? • Source: Shutterstock

Cancer vaccine research has suffered clinical-stage setbacks over the years, but there have been suggestions that combining them with checkpoint inhibitors and other new anticancers has promise. That's cause enough for Germany's mRNA-focused biotech CureVac AG to attract its second big pharma collaborator, Eli Lilly & Co., for its immunotherapy research.

Other potential reasons include the backing of SAP software company founder Dietmar Hopp and the Bill & Melinda Gates Foundation,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.